MaxCyte, Inc. Signing of Strategic Platform License (4333Y)
May 04 2023 - 8:05AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 4333Y
MaxCyte, Inc.
04 May 2023
MaxCyte Signs Strategic Platform License with Walking Fish
Therapeutics to Support the Development of its Innovative B Cell
platform
Walking Fish to use MaxCyte's Flow Electroporation(R) technology
and ExPERT(TM) platform to engineer novel B-cell based medicines
for the treatment of serious diseases
ROCKVILLE, MD, May 4, 2023 - MaxCyte, Inc. , (Nasdaq: MXCT; LSE:
MXCT), a leading, cell-engineering focused company providing
enabling platform technologies to advance the discovery,
development and commercialization of next-generation cell-based
therapeutics and to support innovative, cell-based research, today
announced the signing of a strategic platform license (SPL) with
Walking Fish Therapeutics , Inc. a biotechnology company that is
rapidly advancing B cell-based therapeutics.
Under the terms of the agreement, Walking Fish obtains
non-exclusive clinical and commercial rights to use MaxCyte's Flow
Electroporation(R) technology and ExPERT(TM) platform. In return,
MaxCyte is entitled to receive platfo rm licensing fees, clinical
milestone payments and sales-based payments.
"We are delighted to partner with Walking Fish to help advance
their B cell platform and support their innovative approach to
develop novel therapies for the treatment of serious diseases,"
said Doug Doerfler, President and CEO of MaxCyte.
Walking Fish is a privately held biotechnology company
discovering and developing innovative therapeutics that harness the
power of B cells as protein factories and immune modulators.
Walking Fish has created a broad technology platform addressing
enzyme replacement therapies, oncology, autoimmune disease, and
recombinant antibody production. Walking Fish's first program,
WFX-001 employs B cells as protein factories to generate a
deficient enzyme in Fabry disease .
MaxCyte's ExPERT(TM) instrument portfolio is the next generation
of leading, clinically-validated electroporation technology for
complex and scalable cell engineering. By delivering high
transfection efficiency, seamless scalability and enhanced
functionality, the ExPERT(TM) platform delivers the high-end
performance essential to enabling the next wave of biological and
cellular therapeutics. Walking Fish is MaxCyte's 20th strategic
partnership overall, each of which generates pre-commercial
milestone revenue and the vast majority of which include
sales-based payments.
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize
the potential of cells to improve patients' lives. We have spent
more than 20 years honing our expertise by building best-in-class
platforms, perfecting the art of the transfection workflow, and
venturing beyond today's processes to innovate tomorrow's
solutions. Our ExPERT(TM) platform, which is based on our Flow
Electroporation technology, has been designed to support the
rapidly expanding cell therapy market and can be utilized across
the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM), GTx(TM)
and VLx(TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology, as well as technical and
regulatory support, we aim to guide them on their journey to
transform human health. Learn more at maxcyte.com and follow us on
Twitter and LinkedIn .
About Walking Fish Therapeutics
A leader in B cell medicines, Walking Fish Therapeutics
discovers and develops innovative therapeutics that harness the
power of B cells as protein factories and immune modulators to
treat has made critical advances in engineering technologies to
rapidly advance cell-based therapeutics to treat serious diseases,
concentrating on oncology, rare diseases, oncology, autoimmune
disease, and other life-threatening conditions. For more
information and important updates, please visit walkingfishtx.com
.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Spectrum Seismic Collaborative
Valerie Enes
+1 408-497-8568
valerie@spectrumscience.com
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCAIMPTMTIMMAJ
(END) Dow Jones Newswires
May 04, 2023 08:05 ET (12:05 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024